Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.16
QDEL's Cash-to-Debt is ranked lower than
60% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. QDEL: 1.16 )
Ranked among companies with meaningful Cash-to-Debt only.
QDEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 1.29 Max: No Debt
Current: 1.16
Equity-to-Asset 0.53
QDEL's Equity-to-Asset is ranked lower than
60% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. QDEL: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
QDEL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07  Med: 0.76 Max: 0.92
Current: 0.53
-0.07
0.92
Debt-to-Equity 0.71
QDEL's Debt-to-Equity is ranked lower than
74% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. QDEL: 0.71 )
Ranked among companies with meaningful Debt-to-Equity only.
QDEL' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.5  Med: 0.17 Max: 1.11
Current: 0.71
-8.5
1.11
Interest Coverage 1.38
QDEL's Interest Coverage is ranked lower than
92% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. QDEL: 1.38 )
Ranked among companies with meaningful Interest Coverage only.
QDEL' s Interest Coverage Range Over the Past 10 Years
Min: 0.23  Med: 7.77 Max: 68.51
Current: 1.38
0.23
68.51
Piotroski F-Score: 5
Altman Z-Score: 5.90
Beneish M-Score: -2.74
WACC vs ROIC
10.83%
2.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 7.59
QDEL's Operating Margin % is ranked higher than
61% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. QDEL: 7.59 )
Ranked among companies with meaningful Operating Margin % only.
QDEL' s Operating Margin % Range Over the Past 10 Years
Min: -13.49  Med: 4.48 Max: 31.99
Current: 7.59
-13.49
31.99
Net Margin % -0.03
QDEL's Net Margin % is ranked higher than
55% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. QDEL: -0.03 )
Ranked among companies with meaningful Net Margin % only.
QDEL' s Net Margin % Range Over the Past 10 Years
Min: -9.94  Med: 3.69 Max: 20.02
Current: -0.03
-9.94
20.02
ROE % -0.04
QDEL's ROE % is ranked higher than
54% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. QDEL: -0.04 )
Ranked among companies with meaningful ROE % only.
QDEL' s ROE % Range Over the Past 10 Years
Min: -9.43  Med: 3.04 Max: 26.77
Current: -0.04
-9.43
26.77
ROA % -0.02
QDEL's ROA % is ranked higher than
58% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. QDEL: -0.02 )
Ranked among companies with meaningful ROA % only.
QDEL' s ROA % Range Over the Past 10 Years
Min: -5.92  Med: 2.4 Max: 21.27
Current: -0.02
-5.92
21.27
ROC (Joel Greenblatt) % 22.29
QDEL's ROC (Joel Greenblatt) % is ranked higher than
67% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. QDEL: 22.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
QDEL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -33.25  Med: 11.53 Max: 145.36
Current: 22.29
-33.25
145.36
3-Year Revenue Growth Rate 4.90
QDEL's 3-Year Revenue Growth Rate is ranked lower than
54% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. QDEL: 4.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
QDEL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -14  Med: 4.9 Max: 20.5
Current: 4.9
-14
20.5
3-Year EBITDA Growth Rate -13.00
QDEL's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. QDEL: -13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
QDEL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -58.5  Med: -7.8 Max: 245.9
Current: -13
-58.5
245.9
GuruFocus has detected 3 Warning Signs with Quidel Corp $QDEL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» QDEL's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

QDEL Guru Trades in Q3 2016

Jim Simons 484,300 sh (+19.67%)
Mario Gabelli 626,100 sh (unchged)
» More
Q4 2016

QDEL Guru Trades in Q4 2016

Jim Simons 502,200 sh (+3.70%)
Mario Gabelli 626,100 sh (unchged)
» More
Q1 2017

QDEL Guru Trades in Q1 2017

Steven Cohen 497,600 sh (New)
Mario Gabelli 626,100 sh (unchged)
Jim Simons 479,900 sh (-4.44%)
» More
Q2 2017

QDEL Guru Trades in Q2 2017

Joel Greenblatt 31,536 sh (New)
Paul Tudor Jones 15,080 sh (New)
Jim Simons 612,487 sh (+27.63%)
Mario Gabelli 626,100 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 New Buy0.01%$22.42 - $27.54 $ 42.3071%31,536
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NAS:FMI, NAS:AXDX, NAS:VREX, NAS:MEDP, NAS:GHDX, NAS:BEAT, NAS:ABAX, NAS:ALOG, NAS:NRCIB, NAS:NEO, NAS:NTRA, NAS:LNTH, NAS:HSKA, NAS:VIVO, NAS:PACB, NAS:MYGN, NAS:RDNT, NYSE:ENZ, NYSE:NVTA, NYSE:ARA » details
Traded in other countries:QL1.Germany,
Headquarter Location:USA
Quidel Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. It includes applications in infectious diseases, women's health and gastrointestinal diseases.

Quidel Corp is a corporation, originally incorporated as Monoclonal Antibodies, Inc. in California in 1979 and re-incorporated as Quidel Corporation in the State of Delaware in 1987. The Company is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions include applications in infectious diseases, women's health and gastrointestinal diseases. It sells products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. It markets its products in the United States through a network of national and regional distributors, and through a direct sales force. Internationally, it markets through distributor arrangements. The Company commenced its operations in 1979 and launched its first products, dipstick-based pregnancy tests, in 1983. In February 2010, it expanded its operations through the acquisition of Diagnostic Hybrids, Inc., a privately-held, in vitro diagnostics (IVD) company, based in Athens, Ohio. In 2013, it completed two further acquisitions, acquiring BioHelix Corporation, a developer and manufacturer of isothermal molecular assays and enzymes, in May 2013, and acquiring the assets of AnDiaTec GmbH, a German based developer and manufacturer of molecular assays, in August 2013. The Company's customers for IVD products are centralized laboratories and physician offices and decentralized point-of-care settings. It provides diagnostic testing solutions under various brand names, including, among others, - Quidel, QuickVue, QuickVue+, Sofia, AmpliVue, Solana, Virena, MicroVue, Lyra, FreshCells, D3, FastPoint, ReadyCells, Super E-Mix, ELVIRA, ELVIS and Thyretain. The diagnostic testing solutions are provided through a number of proprietary platforms, including Fluorescent Immunoassays; Molecular Assays; Molecular Systems in Development; and Connectivity and Data Management. The products under medical and wellness categories are Infectious Diseases - Influenza, Streptococci, RSV, Multiplex Respiratory, General Virology, Herpes and Herpes Family; POC Women's and General Health - Pregnancy, Graves Disease, Chlamydia, Bone Health; Bone Health, Autoimmune Disease and Oncology; Gastrointestinal Diseases - Clostridium difficile, Enterovirus, Helicobacter pylori, Immunoassay fecal occult blood. The Company has two manufacturing sites in San Diego, California and Athens, Ohio. San Diego facility consists of laboratories devoted to tissue culture, cell culture, protein purification and immunochemistry and production areas dedicated to manufacturing and assembly. Athens facility consists of clean rooms (FS-209E Class 1000: ISO Class 6) for the culturing and dispensing of cell cultures under cGMP conditions. The facility also has laboratories devoted to tissue culture for the production of monoclonal an

Top Ranked Articles about Quidel Corp

Douglas Bryant Sells Quidel Corp The CEO and president sold 69,168 shares
Douglas Bryant (Insider Trades), CEO and president of Quidel Corp. (NASDAQ:QDEL), sold 69,168 shares of the company on Sept. 30. The average price per share was $21.76, for a total transaction of $1,505,096. Quidel, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has a market cap of $704.21 million. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 51.28
QDEL's Forward PE Ratio is ranked lower than
69% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. QDEL: 51.28 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 198.45
QDEL's Price-to-Owner-Earnings is ranked lower than
59% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. QDEL: 198.45 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
QDEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.95  Med: 25.89 Max: 467.6
Current: 198.45
5.95
467.6
PB Ratio 6.64
QDEL's PB Ratio is ranked lower than
51% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. QDEL: 6.64 )
Ranked among companies with meaningful PB Ratio only.
QDEL' s PB Ratio Range Over the Past 10 Years
Min: 2.12  Med: 3.52 Max: 6.78
Current: 6.64
2.12
6.78
PS Ratio 6.58
QDEL's PS Ratio is ranked lower than
55% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. QDEL: 6.58 )
Ranked among companies with meaningful PS Ratio only.
QDEL' s PS Ratio Range Over the Past 10 Years
Min: 1.83  Med: 3.95 Max: 6.71
Current: 6.58
1.83
6.71
Price-to-Free-Cash-Flow 60.29
QDEL's Price-to-Free-Cash-Flow is ranked lower than
51% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. QDEL: 60.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
QDEL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.92  Med: 24.94 Max: 393
Current: 60.29
5.92
393
Price-to-Operating-Cash-Flow 37.19
QDEL's Price-to-Operating-Cash-Flow is ranked higher than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. QDEL: 37.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
QDEL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.34  Med: 20.4 Max: 75.3
Current: 37.19
5.34
75.3
EV-to-EBIT 85.55
QDEL's EV-to-EBIT is ranked lower than
81% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QDEL: 85.55 )
Ranked among companies with meaningful EV-to-EBIT only.
QDEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -183.3  Med: 22.85 Max: 591
Current: 85.55
-183.3
591
EV-to-EBITDA 36.38
QDEL's EV-to-EBITDA is ranked lower than
53% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. QDEL: 36.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
QDEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -180.4  Med: 19.2 Max: 189.5
Current: 36.38
-180.4
189.5
EV-to-Revenue 6.49
QDEL's EV-to-Revenue is ranked higher than
50% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. QDEL: 6.49 )
Ranked among companies with meaningful EV-to-Revenue only.
QDEL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 3.8 Max: 6.6
Current: 6.49
1.8
6.6
Shiller PE Ratio 241.42
QDEL's Shiller PE Ratio is ranked lower than
94% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. QDEL: 241.42 )
Ranked among companies with meaningful Shiller PE Ratio only.
QDEL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 37.84  Med: 75.15 Max: 260.67
Current: 241.42
37.84
260.67
Current Ratio 7.19
QDEL's Current Ratio is ranked higher than
88% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. QDEL: 7.19 )
Ranked among companies with meaningful Current Ratio only.
QDEL' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.36 Max: 9.88
Current: 7.19
1.64
9.88
Quick Ratio 6.46
QDEL's Quick Ratio is ranked higher than
85% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. QDEL: 6.46 )
Ranked among companies with meaningful Quick Ratio only.
QDEL' s Quick Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.32 Max: 7.76
Current: 6.46
1.12
7.76
Days Inventory 110.17
QDEL's Days Inventory is ranked lower than
62% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. QDEL: 110.17 )
Ranked among companies with meaningful Days Inventory only.
QDEL' s Days Inventory Range Over the Past 10 Years
Min: 77.63  Med: 103.27 Max: 130.34
Current: 110.17
77.63
130.34
Days Sales Outstanding 33.82
QDEL's Days Sales Outstanding is ranked higher than
83% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. QDEL: 33.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
QDEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.59  Med: 54.61 Max: 76.33
Current: 33.82
21.59
76.33
Days Payable 52.36
QDEL's Days Payable is ranked lower than
61% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. QDEL: 52.36 )
Ranked among companies with meaningful Days Payable only.
QDEL' s Days Payable Range Over the Past 10 Years
Min: 29.04  Med: 40.05 Max: 79.78
Current: 52.36
29.04
79.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.20
QDEL's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. QDEL: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
QDEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -59.3  Med: -4.2 Max: 4.7
Current: 1.2
-59.3
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 35.85
QDEL's Price-to-Net-Current-Asset-Value is ranked lower than
64% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. QDEL: 35.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
QDEL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.45  Med: 13.98 Max: 272.83
Current: 35.85
3.45
272.83
Price-to-Tangible-Book 15.49
QDEL's Price-to-Tangible-Book is ranked lower than
69% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. QDEL: 15.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
QDEL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.15  Med: 5.34 Max: 15.8
Current: 15.49
1.15
15.8
Price-to-Intrinsic-Value-Projected-FCF 5.57
QDEL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. QDEL: 5.57 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
QDEL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.98  Med: 2.85 Max: 70.83
Current: 5.57
0.98
70.83
Price-to-Median-PS-Value 1.67
QDEL's Price-to-Median-PS-Value is ranked lower than
51% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. QDEL: 1.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
QDEL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.67 Max: 1.7
Current: 1.67
0.26
1.7
Earnings Yield (Greenblatt) % 1.17
QDEL's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. QDEL: 1.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
QDEL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.3  Med: 2.1 Max: 17.6
Current: 1.17
-3.3
17.6
Forward Rate of Return (Yacktman) % -0.56
QDEL's Forward Rate of Return (Yacktman) % is ranked lower than
75% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. QDEL: -0.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
QDEL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.8  Med: 2.4 Max: 49.7
Current: -0.56
-8.8
49.7

More Statistics

Revenue (TTM) (Mil) $214.11
EPS (TTM) $ -0.01
Beta1.51
Short Percentage of Float16.56%
52-Week Range $18.25 - 45.55
Shares Outstanding (Mil)33.44

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 230 245
EPS ($) 0.76 0.84
EPS without NRI ($) 0.76 0.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Douglas Bryant Sells Quidel Corp. Oct 03 2016 
Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic T Mar 17 2015 
Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering Dec 02 2014 
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parain Oct 15 2014 
Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus Oct 15 2014 
Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014 Oct 15 2014 
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 

More From Other Websites
Quidel Corporation (QDEL) Jumps: Stock Rises 6.5% Sep 20 2017
Here's Why Quidel Corporation Stock Is Popping Today Sep 19 2017
Quidel Announces Revised Agreement for Its Pending Acquisition of Alere’s B-type Naturietic... Sep 18 2017
Quidel to Participate in the CEO Series Conference Call Hosted by Canaccord Genuity Sep 08 2017
ETFs with exposure to Quidel Corp. : August 15, 2017 Aug 15 2017
Edited Transcript of QDEL earnings conference call or presentation 24-Apr-17 9:00pm GMT Aug 13 2017
Quidel Corp. :QDEL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Aug 01 2017
Quidel to Present at the 37th Annual Canaccord Genuity Growth Conference Jul 31 2017
Quidel reports 2Q loss Jul 27 2017
Quidel Reports Second Quarter 2017 Financial Results Jul 26 2017
Alere, St. Jude Deals in Focus as Abbott Releases Q2 Earnings Jul 19 2017
Corporate News Blog - Quidel to Acquire Alere Triage(R) Assets Jul 19 2017
Quidel Diversifies With Alere's Triage Assets Jul 18 2017
Abbott's Tarnished Deal Sparkles for Another Jul 18 2017
Here's Why Quidel Corporation Is Rising Today Jul 18 2017
Quidel (QDEL) Worth a Look: Stock Jumps 25.4% in Session Jul 18 2017
Quidel Announces Definitive Agreement to Acquire Alere Triage® Assets Jul 17 2017
Quidel to Hold Second Quarter 2017 Financial Results Conference Call on July 26, 2017 Jul 14 2017
Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Instrument for Use... Jun 28 2017
Quidel’s Sofia® 2 Point-of-Care Immunoassay Analyzer Receives Multiple Awards from Good Design... Jun 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}